Long‐term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B
Patrick Marcellin, Ting‐Tsung Chang, Seng G. Lee Lim, William Sievert, Myron Tong, Sarah Arterburn, Katyna Borroto‐Esoda, David Frederick, Franck Rousseau – 16 May 2008 – Treatment of 171 patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B (CHB) with adefovir dipivoxil (ADV) 10 mg over 48 weeks resulted in significant histological, virological, serological, and biochemical improvement compared with placebo. The long‐term efficacy and safety of ADV in a subset of these patients was investigated for up to 5 years.